ArticleJournal of breast cancer2026
Sentinel Lymph Node Analysis in Patients With Breast Cancer Revealed Alterations in T Cells Subset.
Article in Journal of breast cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
In breast cancer, sentinel lymph nodes (SLNs) represent the first site of interaction between tumor-derived antigens and the host immune system. However, descriptive data on immune cell subsets within the SLN remains limited. This exploratory study evaluated immune cell populations in SLN samples from women with invasive breast cancer (IBC) using flow cytometry, and assessed their distribution according to clinicopathological characteristics. SNL scrapings were collected from 22 patients with IBC. SNL cells were evaluated using flow cytometry, and the results were compared with clinical and pathological variables, such as tumor subtype, axillary status, lymphovascular invasion (LVI), histological grades, and expression of estrogen receptors (ERs) and human epidermal growth factor receptor 2 (HER2). The frequencies of monocytes and neutrophils were not significantly correlated with the clinical variables analyzed. In patients with LVI, there was an increase in the frequency of CD4⁺ T cells and programmed death-1 (PD-1) expression in CD8⁺ T-cells. Furthermore, a reduction in central memory CD4⁺ T cells and an increase in terminal effector memory CD4⁺ T cells were observed in patients with histological grade III disease compared to those with histological grade I disease. It was also observed that in patients expressing ERs and HER2, there was an increase in PD-1 and programmed death-ligand 1 expression in CD8⁺ T-cells. These findings provide a descriptive overview of immune cell distribution in SLNs according to their clinicopathological features. These results are preliminary and hypothesis-generating, supporting the need for larger longitudinal studies to further characterize the immune profiles within tumor-draining lymph nodes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.